Yseop’s impactful Generative AI capabilities helping accelerate drugs to market
At the same time, the company has announced the closing of a strategic investment round with new investor Novartis (dRx Capital) joining existing investors Eli Lilly, Next Stage AM and Wille Finance. Included in the trials, Yseop says, are many of the most notable advancements in new treatments, vaccines and medicines that have emerged recently.
Read More